The global type 2 diabetes drugs market is expected to grow at a CAGR of 7.28% during the period 2016-2020.
Type 2 diabetes accounts for nearly 90%-95% of the total number of diabetes cases worldwide and is primarily diagnosed in the middle-aged and old age groups, i.e., between the ages of 30 and 75 years. However, it can occur even during childhood. The risks of type 2 diabetes include high blood pressure, advancing age, obesity, history of gestational diabetes, family history of diabetes, poor nutrition during pregnancy, physical inactivity, and impaired glucose tolerance.
The growing awareness of type 2 diabetes and the treatments available for it, as a result of national and global initiatives, drives the market. The increase in the diabetic population has increased accessibility to disease monitoring and disease management devices, and key vendors have begun to focus on emerging markets such as China.
According to the report, obesity, unhealthy diets, and lack of physical activity have increased the number of diabetes cases worldwide. As reported by WHO, it was estimated that 9% of the adults who are 18 years and above had diabetes in 2014. It was also reported that the global prevalence of diabetes would be around 366 million by 2030. In 2013, nearly 21 million live births were affected by diabetes during pregnancy. An increase in the exposure to the risk factors for type 2 diabetes in low- and middle-income groups is increasing in Middle East, North Africa, Southeast Asian, and Western Pacific regions.
Further, the report states that low diagnosis rate impedes people from availing the treatment, posing a challenge for the market.
- AstraZeneca plc
- Eli Lilly and Company
- Merck & Co. Inc.
- Novo Nordisk A/S
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Disease overview
PART 06: Pipeline portfolio
PART 07: Market landscape
PART 08: Market segmentation by drug class
PART 09: Insulin
PART 10: DPP-4 inhibitors
PART 11: GLP-1 receptor agonists
PART 12: SGLT-2 inhibitors
PART 13: Geographical segmentation
PART 14: Market drivers
PART 15: Impact of drivers
PART 16: Market challenges
PART 17: Impact of drivers and challenges
PART 18: Market trends
PART 19: Vendor landscape
For more information visit http://www.researchandmarkets.com/research/f9xqt4/global_type_2